SCHEMBL6184504

SCHEMBL6184504

C=C(C)CC(NC(=O)c1ccc(N2CCOCC2)cc1)C(=O)NCC#N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 12/20 0.67
CTSK P43235 7/20 0.56
CTSS P25774 6/20 0.52
CTSB P07858 5/20 0.52
JAK2 O60674 3/20 0.47
JAK3 P52333 3/20 0.47
BMPR1B O00238 1/20 0.47
PLK4 O00444 1/20 0.47
CIT O14578 1/20 0.47
GAK O14976 1/20 0.47
OPA1 O60313 1/20 0.47
ROCK2 O75116 1/20 0.47
STK16 O75716 1/20 0.47
PRKD3 O94806 1/20 0.47
CSNK2A2 P19784 1/20 0.47
JAK1 P23458 1/20 0.47
CDK2 P24941 1/20 0.47
MARK3 P27448 1/20 0.47
TYK2 P29597 1/20 0.47
BMPR1A P36894 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183695 0.85 CTSK (0.75) CTSLCTSKCTSSCTSB
SCHEMBL6184505 0.83 CTSL (0.44) CTSLCTSKCTSSCTSBMAPT
SCHEMBL6182818 0.80 CTSL (1.00) CTSLCTSKCTSSCTSB
SCHEMBL6183050 0.80 CTSK (0.70) CTSLCTSKCTSSCTSB
SCHEMBL6208306 0.80 CTSL (0.53) CTSLCTSKCTSSCTSB
SCHEMBL6208313 0.80 CTSL (0.53) CTSLCTSKCTSSCTSB
SCHEMBL6265763 0.79 CTSL (0.52) CTSLCTSKCTSSCTSB
SCHEMBL6265766 0.79 CTSL (0.52) CTSLCTSKCTSSCTSB
SCHEMBL6181110 0.78 CTSL (0.73) CTSLCTSKCTSSCTSB
SCHEMBL6266810 0.78 CTSL (0.50) CTSLCTSKCTSSCTSBJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSL 14/4885CTSK 32/4885CTSS 10/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSL 14/4885CTSK 32/4885CTSS 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.